Present and future of FDG-PET/CT in ovarian cancer

Annals of Nuclear Medicine

Volumn 25, Issue 3, 2011, Pages 155-164

  Kitajima, Kazuhiro ^a   Murakami, Koji ^b   Sakamoto, Setsu ^c   Kaji, Yasushi ^c   Sugimura, Kazuro ^d  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d KOBE UNIVERSITY   (Japan)

Author keywords

FDG; Ovarian cancer; PET CT; Restaging; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79959992869     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0449-8     Document Type: Review

References (58)

1. Bristow RE, Duska LR, Lambrou NC, Fishmann EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532-40.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-79. (Pubitemid 30643379)
4. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238: 405-22. (Pubitemid 43134354)
5. Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF. FDG PET/CT in oncology: ''raising the bar''. Clin Radiol. 2010;65: 522-35.
6. Adusumili S, Hussain HK, Caoili EM, Weadock WJ, Murray JP, Johnson TD, et al. MRI of sonographically indeterminate adnexal masses. AJR Am J Roentgenol. 2006;187:732-40. (Pubitemid 44651498)
7. Booth SJ, Turnbull LW, Poole DR, Richmond I. The accurate staging of ovarian cancer using 3T magnetic resonance imaging- a realistic option. BJOG. 2008;15:894-901. (Pubitemid 351692995)
8. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol. 2007;105: 145-9. (Pubitemid 46454333)
9. Castelluci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589-95. (Pubitemid 47067045)
10. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116:389-94.
11. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138-50.
12. Ricke J, Sehouli J, Hach C, Hanninen EL, Lichtenegger W, Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol. 2003;13:943-9. (Pubitemid 36790585)
13. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrastenhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1912-20.
14. Namimoto T, Awai K, Nakaura T, Yanaga Y, Hirai T, Yamashita Y. Role of diffusion-weighted imaging in the diagnosis of gynecological diseases. Eur Radiol. 2009;19:745-60.
15. Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2008;18:18-23. (Pubitemid 351217273)
16. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol. 2003;88:9-16. (Pubitemid 36062659)
17. Schwarz JK, Grigsby PW, Dehdashti F, Celbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50:64S-73S.
18. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, et al. Performance of integrated FDG-PET/contrastenhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast- enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1439-48.
19. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bosckisch A, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J of Radiol. 2005;56: 263-8. (Pubitemid 41483027)
20. Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P, et al. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792-7. (Pubitemid 41194659)
21. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271-6. (Pubitemid 44374699)
22. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480-6. (Pubitemid 46426988)
23. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658-66. (Pubitemid 46669366)
24. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17-22. (Pubitemid 46441448)
25. Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr. 2007;31:868-75. (Pubitemid 350196929)
26. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008;33:112-8.
27. Iagaru AH, Mittra ES, McDougall IR, Quon A, Gambhir SS. 18FFDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun. 2008;29:1046-51.
28. Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET/CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008;108:160-5. (Pubitemid 350299439)
29. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET/CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET data collection project. Gynecol Oncol. 2009;112:462-8.
30. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85: 53-8. (Pubitemid 34304010)
31. Bristow RE, Del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90:519-28.
32. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garevaglia E, et al. Integrated FDG-PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004;233:433-40. (Pubitemid 39423802)
33. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PETCT detection of abdominal recurrence of ovarian cancer: radiologic- surgical correlation. Abdom Imaging. 2004;39:398-403. (Pubitemid 38590822)
34. Bristow RE, Giuntoli RL II, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol. 2005;99:294-300. (Pubitemid 41502833)
35. Rose PG. Surgery for recurrent ovarian cancer. Semin Oncol. 2000;27:17-23. (Pubitemid 30643848)
36. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164-74.
37. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging. 1999;2:63-70.
38. Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:196-201. (Pubitemid 38173694)
39. Nishiyama Y, Yamamoto Y, Kaneishi K, Ohno M, Hata T, Kushida Y, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging. 2008;35:287-95.
40. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-53. (Pubitemid 46291806)
41. Kurosaki H, Oriuchi N, Okazaki A, Tamaki T, Uki A, Izuta M, et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med. 2006;20: 171-4. (Pubitemid 43925959)
42. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer. Gynecol Oncol. 2010;116:395-8.
43. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009;19:1529-36.
44. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET alone and enhanced CT alone. Eur J Nucl Med Mol Imaging. 2009;36:362-72.
45. Kitajima K, Suzuki K, Nakamoto Y, Onishi Y, Sakamoto S, Senda M, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging. 2010;37:1490-8.
46. Bunyaviroch T, Turkington TG, Wong TZ, Wilson JW, Colsher JG, Coleman RE. Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol. 2008;10:107-13.
47. Kumar R, Chauhan A, Jana S, Dadparvar S. Positron emission tomography in gynaecological malignancies. Expert Rev Anticancer Ther. 2006;6:1033-44. (Pubitemid 44203381)
48. Koyama K, Okamura T, Kawabe J, Ozawa N, Torii K, Umesaki N, et al. Evaluation of 18FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med. 2003; 44:353-8. (Pubitemid 39586010)
49. Belhocine T, Thille A, Fridman V, Albert A, Seidel L, Nickers P, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol. 2002;87:90-7. (Pubitemid 36027107)
50. Prakash P, Cronin CG, Blake MA. PET/CT in ovarian cancer. AJR Am J Roentgenol. 2010;194:W464-70.
51. Kim SK, Kang KW, Roh JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005;32: 757-63.
52. Domingues RC, Carneiro MP, Lopes FCR, Domingues RC, Fonseca LMB, Gasparetto EL. Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol. 2009;192:1012-20.
53. Yoshida Y, Kurokawa T, Tsujikawa T, Okazawa H, Kotsuji F. Positron emission tomography in ovarian cancer: 18F-deoxyglucose and 16a-18F-fluoro-17b- estradiol(FES) PET. J Ovarian Res. 2009;2:7-16.
54. Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynaecologic tumor: comparison of 11C-Choline PET with 18F-FDG PET. J Nucl Med. 2003; 44:1051-6. (Pubitemid 39663379)
55. Ludemann L, Sreenivasa G, Amthauer H, Michel R, Gellermann J, Wust P. Use of H2 15O-PET for investigating perfusion changes in pelvic tumors due to regional hyperthermia. Int J Hyperth. 2009;25:299-308.
56. Antoch G, Bockisch A. Combined. PET/MRI: a dimension of whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36:S113-20.
57. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-6.
58. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med. 2008;38:199-208. (Pubitemid 351466918)